MXPA05006650A - Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos. - Google Patents
Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.Info
- Publication number
- MXPA05006650A MXPA05006650A MXPA05006650A MXPA05006650A MXPA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- independently
- ring
- indol
- sulfonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 102000002933 Thioredoxin Human genes 0.000 abstract 2
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 abstract 2
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 abstract 2
- 150000002148 esters Chemical group 0.000 abstract 2
- 229940094937 thioredoxin Drugs 0.000 abstract 2
- 108060008226 thioredoxin Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000001033 ether group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Esta invencion se refiere a ciertos compuestos de 4-(1- (sulfonil)-1H-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos, incluyendo compuestos de la siguiente formula, los cuales son, entre otros, agentes antiproliferativos, agentes contra el cancer y/o inhibidores de tiorredoxina/tiorredoxina reductasa: (ver formula) en donde: Ar es un grupo 1-(sulfonil)-1H-indol-2-ilo; el enlace marcado a es independientemente: (a) un solo enlace o (b) un doble enlace; el enlace marcado ° es independientemente: (a) un solo enlace o (b) un doble enlace; el grupo -OR° es independientemente: (a) -OH; (b) un grupo de eter (por ejemplo, -OMe) o (c) un grupo aciloxi (es decir, ester inverso) (por ejemplo, -OC(=O)Me); cada uno de R2, R3, R5 y es independientemente un sustituyente de anillo y es: (a) H; (b) un sustituyente monodentado monovalente o (c) un sustituyente de anillo que, junto con un sustituyente de anillo adyacente, y junto con los atomos de anillo a los cuales estos sustituyentes de anillo estan unidos, forman un anillo fusionado; y sales, esteres, amidas, solvatos, hidratos y formas protegidas farmaceuticarnente aceptables de los mismos. La presente invencion se refiere tambien a composiciones farmaceuticas que comprenden estos compuestos, asi como al uso de estos compuestos y composiciones, tanto in vitro como in vivo, por ejemplo, en el tratamiento de condiciones proliferativas (por ejemplo cancer), y/o condiciones mediadas por tiorredoxina/tiorredoxina reductasa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2002/005842 WO2004056361A1 (en) | 2002-12-20 | 2002-12-20 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05006650A true MXPA05006650A (es) | 2005-09-30 |
Family
ID=32670966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05006650A MXPA05006650A (es) | 2002-12-20 | 2002-12-20 | Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7307099B2 (es) |
| EP (1) | EP1572197B1 (es) |
| JP (1) | JP4465281B2 (es) |
| CN (1) | CN100363347C (es) |
| AT (1) | ATE437639T1 (es) |
| AU (1) | AU2002353193B2 (es) |
| BR (1) | BR0215986A (es) |
| CA (1) | CA2508275A1 (es) |
| DE (1) | DE60233175D1 (es) |
| ES (1) | ES2330205T3 (es) |
| MX (1) | MXPA05006650A (es) |
| WO (1) | WO2004056361A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003670B2 (en) * | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
| GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
| CN102051406A (zh) * | 2009-11-03 | 2011-05-11 | 凯熙医药(武汉)有限公司 | 一种用于预报人体发生异常增殖或肿瘤发生风险的检测方法 |
| EP4460506A1 (en) * | 2022-01-07 | 2024-11-13 | University of Maryland, Baltimore | Estradiol prodrugs and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535165A (en) | 1981-11-23 | 1985-08-13 | Riker Laboratories, Inc. | Substituted diazoles and thiazoles |
| US4357345A (en) | 1981-11-23 | 1982-11-02 | Riker Laboratories, Inc. | Substituted furans |
| US4414217A (en) | 1981-11-23 | 1983-11-08 | Riker Laboratories, Inc. | 3,5-Di(t-butyl)-4-hydroxyphenyl substituted pyridines |
| FR2665441B1 (fr) | 1990-07-31 | 1992-12-04 | Sanofi Sa | Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant. |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| CA2091204C (en) | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
| US5391570A (en) * | 1993-10-14 | 1995-02-21 | Bristol-Myers Squibb | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
| US6794402B2 (en) | 2000-05-31 | 2004-09-21 | Warner-Lambert Company | Bicyclic cyclohexylamines and their use as NMDA receptor antagonists |
| GB0116594D0 (en) * | 2001-07-06 | 2001-08-29 | Cancer Res Ventures Ltd | Therapeutic compounds |
-
2002
- 2002-12-20 MX MXPA05006650A patent/MXPA05006650A/es active IP Right Grant
- 2002-12-20 BR BR0215986-4A patent/BR0215986A/pt active Search and Examination
- 2002-12-20 EP EP02788211A patent/EP1572197B1/en not_active Expired - Lifetime
- 2002-12-20 CN CNB028300815A patent/CN100363347C/zh not_active Expired - Fee Related
- 2002-12-20 AU AU2002353193A patent/AU2002353193B2/en not_active Ceased
- 2002-12-20 JP JP2004561588A patent/JP4465281B2/ja not_active Expired - Fee Related
- 2002-12-20 CA CA002508275A patent/CA2508275A1/en not_active Abandoned
- 2002-12-20 US US10/539,451 patent/US7307099B2/en not_active Expired - Fee Related
- 2002-12-20 DE DE60233175T patent/DE60233175D1/de not_active Expired - Lifetime
- 2002-12-20 AT AT02788211T patent/ATE437639T1/de not_active IP Right Cessation
- 2002-12-20 ES ES02788211T patent/ES2330205T3/es not_active Expired - Lifetime
- 2002-12-20 WO PCT/GB2002/005842 patent/WO2004056361A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR0215986A (pt) | 2005-11-01 |
| JP4465281B2 (ja) | 2010-05-19 |
| WO2004056361A1 (en) | 2004-07-08 |
| CA2508275A1 (en) | 2004-07-08 |
| ATE437639T1 (de) | 2009-08-15 |
| US20060100265A1 (en) | 2006-05-11 |
| JP2006512351A (ja) | 2006-04-13 |
| ES2330205T3 (es) | 2009-12-07 |
| AU2002353193A1 (en) | 2004-07-14 |
| CN100363347C (zh) | 2008-01-23 |
| US7307099B2 (en) | 2007-12-11 |
| DE60233175D1 (de) | 2009-09-10 |
| CN1717233A (zh) | 2006-01-04 |
| EP1572197A1 (en) | 2005-09-14 |
| AU2002353193B2 (en) | 2010-03-25 |
| EP1572197B1 (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2023012361A (es) | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. | |
| MX2009000871A (es) | Novedosos inhibidores de transcriptasa inversa de vih. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MY210357A (en) | Modulators of thr-beta with a dioxo-1,2,4-triazyl | |
| MX2009013804A (es) | Inhibidores novedosos de transcriptasa inversa de vih. | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| WO2024141128A3 (zh) | Sting抑制剂前药及其医药用途 | |
| MY148125A (en) | Compounds | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| TW200630364A (en) | 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| GB0116594D0 (en) | Therapeutic compounds | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| TW200510384A (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| DE60114640D1 (en) | Antithrombosemittel | |
| MXPA05006650A (es) | Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos. | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
| MX2023006176A (es) | Nuevos derivados de indazol acetileno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |